Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Mediso reaches another milestone with 150th installation of preclinical integrated multimodality imaging system

Mediso Medical Equipment Developing and Service Ltd. is proud to announce the hundred and fiftieth installation of Mediso manufactured, integrated preclinical imaging systems, at the prestigious Edinburgh University.

September 22, 2014

Video lecture: Nanoconstructs in theranostics

Watch a presentation on nanoconstructs in cancer theranostics from the Methodist Hospital Research Institute and Tel Aviv University (TAU) posted online from the recent Summer School on Nanomedicine and Innovation.

September 15, 2014

Mevion Medical Systems introduces Hyperscan for the Mevion S250 platform

Hyperscan is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco.  Mevion representatives will formally introduce Hyperscan at booth 728 in the exhibit hall.

September 15, 2014

Agendia test for molecular subtyping of breast cancer is a better guide to pre-surgical treatment

In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing.

September 15, 2014

Eli Lilly funds lawsuit against CMS for limiting amyloid imaging

Makers of F-18 florbetapir (Amyvid) are bankrolling a lawsuit against the Centers for Medicare & Medicaid Services (CMS), which hampered coverage of amyloid imaging earlier this year as a means for ruling out Alzheimer’s disease. The lawsuit was filed in federal court by Lilly and others Sept. 5, according to this Wall Street Journal report.

September 15, 2014
analyzing financial data

CMS: Slow growth in U.S. health spending

The Centers for Medicare & Medicaid Services (CMS) has provided projected U.S. healthcare spending for the next several years and it is modest. Due to a timid economy and higher private insurance plan costs that pinch demand for healthcare services, average annual healthcare spending is expected to grow by 5.7 percent this year and just about 6 percent from 2013 to 2023.

September 5, 2014

Agendia announces study showing molecular subtyping can improve breast cancer treatment

In findings that may eventually change the way breast cancer is evaluated and treated, a new study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use of conventional IHC-FISH pathology tests.

September 3, 2014

Cancer screening bias casts a shadow on clinical decision making

In the world of cancer screening, there may be a bias of accessibility that is skewed toward more screening when doctors are paid more by Medicaid, according to a study conducted by the division of health services and social policy research at RTI International in Washington, D.C.

August 29, 2014